Pentraxin 3 in Systemic Lupus Erithematosus: Questions to be Resolved
Translational Biomedicine · 2015
DOI: 10.21767/2172-0479.100005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Biomedicine, 2015. Verfasst von Roberto Assandri und 1 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Systemic lupus erythematosus (SLE) is a autoimmune disorder with unpredictable course that involves polyclonal autoimmunity against multiple autoantigens and presents a broad spectrum of clinical manifestations (fever, skin rashes, arthralgia, inflammation of kidney, lungs, or brain). The pathogenesis of SLE is based on a combinations of genetic variants and environmental factor that promote loss-of-tolerance or tissue inflammation. In fact there is growing evidence to suggest that inflammation and related molecules plays a key role in the pathogenesis of SLE. The pentraxin superfamily (PTXs), divided into long and short PTXs, can induce by and a variety of inflammation-associated stimuli. Alongside the classical short pentraxins C-reactive protein (CRP) and serum amyloid P component (SAP), pentraxin 3 ( PTX3) is a prototypic of long pentraxin family, a multifunctional protein characterized by a cyclic multimeric structure and a conserved domain
Zitieren
APA
Assandri, R., & Monari, M. (2015). Pentraxin 3 in Systemic Lupus Erithematosus: Questions to be Resolved. Translational Biomedicine. https://doi.org/10.21767/2172-0479.100005
Vancouver
Assandri R, Monari M. Pentraxin 3 in Systemic Lupus Erithematosus: Questions to be Resolved. Translational Biomedicine. 2015. doi:10.21767/2172-0479.100005
BibTeX
@article{Assandri2015,
author = {Assandri, Roberto and Monari, Marta},
title = {Pentraxin 3 in Systemic Lupus Erithematosus: Questions to be Resolved},
journal = {Translational Biomedicine},
year = {2015},
doi = {10.21767/2172-0479.100005}
}
EUVIMED